Bills › 2023-24
HB 1356: Biosimilar medicines
Data last updated: bill actions through Aug 23, 2026 · lobbyist reports through Sep 30, 2026 (read Oct 14, 2026)
Reducing prescription drug costs by eliminating barriers impeding access to biosimilar medicines.
- Prime sponsor
- Kristine Reeves
- Introduced
- Jan 16, 2023
- Status
- By resolution, reintroduced and retained in present status. (Jan 8, 2024)
- The Legislature's page
- HB 1356 on leg.wa.gov
Floor votes
No floor roll call on file (it didn't pass a chamber, or it was decided without one).
Who lobbied on it 1
| Employer | Lobbyists | To 2026 candidates |
|---|---|---|
| Association for Accessible Medicines | 1 | — |
Lobbying reports name a bill number, not a position on it or a version of it. Money: what each employer (as a donor to two or more 2026 candidates) gave to the 2026 campaigns of the members who voted yea or nay on the bill's latest final passage in each chamber.